Surrozen Inc Quick Ratio (SRZN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Surrozen Inc   (NASDAQ: SRZN)

Surrozen Inc 's Quick Ratio

SRZN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Surrozen Inc 's Cash & cash equivalent, this led to improvement in Surrozen Inc 's Quick Ratio to 0.5, Quick Ratio remained below Surrozen Inc average.

Within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than Surrozen Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2545 to 2629.

Explain Quick Ratio?
How much Cash & cash equivalents SRZN´s has?
What are SRZN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SRZN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 1215.98 % 369.28 % 2187.11 % 830.31 % 158.2 %
Y / Y Cash & cash equivalent Change 12.89 % 5.18 % 158.19 % 162.27 % 139.35 %
Quick Ratio MRQ 0.5 0.44 0.53 1.43 5.85
SRZN's Total Ranking # 2629 # 2545 # 0 # 1370 # 416
Seq. Current Liabilities Change -16.39 % 45.34 % 193.85 % 268.56 % -70.19 %
Seq. Cash & cash equivalent Change -4.56 % 19.79 % 9.73 % -10.02 % -11.07 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 126
Healthcare Sector # 742
Overall Market # 2629


Quick Ratio Statistics
High Average Low
23.72 7.03 0.44
(Mar 31 2021)   (Mar 31 2026)




Financial Statements
Surrozen Inc 's Current Liabilities $ 203 Millions Visit SRZN's Balance sheet
Surrozen Inc 's Cash & cash equivalent $ 102 Millions Visit SRZN's Balance sheet
Source of SRZN's Sales Visit SRZN's Sales by Geography


Cumulative Surrozen Inc 's Quick Ratio

SRZN's Quick Ratio for the trailling 12 Months

SRZN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 731.1 % 577.83 % 1038.81 % 417.16 % 210.59 %
Y / Y Cash & cash equivalent TTM Growth 47.33 % 79.47 % 177.59 % 133.09 % 78.24 %
Quick Ratio TTM 0.57 0.76 1.24 2.34 3.19
Total Ranking TTM # 3987 # 3106 # 0 # 3202 # 2671
Seq. Current Liabilities TTM Growth 38.9 % 65.64 % 121.65 % 62.97 % 13.29 %
Seq. Cash & cash equivalent TTM Growth 3.17 % 1.45 % 17.76 % 19.53 % 25.67 %

Quick ratio ranking by company, industry and sector >> Back to SRZN Financial Strength Comparisons >> Go to Compare SRZN Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q2 2026 to $203.29 millions, cumulative Quick Ratio decreased to 0.57 below the Surrozen Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Surrozen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3106 to 3987.

Explain Quick Ratio?
How much Cash & cash equivalents SRZN´s has?
What are SRZN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 899
Within the Market # 3987


trailing twelve months Quick Ratio Statistics
High Average Low
6.14 3.16 0.24
(Sep 30 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions
Senti Biosciences Holdings Inc   0.83 $ 13.124  Millions$ 15.765  Millions
Pelthos Therapeutics Inc   0.78 $ 24.776  Millions$ 31.959  Millions
Ocugen Inc   0.75 $ 100.051  Millions$ 133.080  Millions
Sab Biotherapeutics Inc   0.71 $ 8.267  Millions$ 11.705  Millions
Vaxcyte Inc   0.68 $ 183.190  Millions$ 271.277  Millions
Halozyme Therapeutics Inc   0.61 $ 231.081  Millions$ 375.965  Millions
Silexion Therapeutics Corp  0.57 $ 2.258  Millions$ 3.976  Millions
Atlantic Coastal Acquisition Corp Ii  0.52 $ 4.291  Millions$ 8.225  Millions
Surrozen Inc   0.50 $ 102.039  Millions$ 203.292  Millions
Pluri Inc   0.40 $ 13.126  Millions$ 32.719  Millions
Outlook Therapeutics Inc   0.39 $ 11.242  Millions$ 28.679  Millions
Neurocrine Biosciences Inc   0.37 $ 390.500  Millions$ 1,046.100  Millions
Curis Inc   0.37 $ 5.100  Millions$ 13.675  Millions
Creative Medical Technology Holdings Inc   0.36 $ 0.250  Millions$ 0.699  Millions
Xtant Medical Holdings Inc   0.33 $ 9.870  Millions$ 29.963  Millions
Champions Oncology Inc   0.23 $ 4.358  Millions$ 18.729  Millions
ADAPTIN BIO, INC.  0.22 $ 0.670  Millions$ 3.036  Millions

Date modified: 2026-09-08T01:25:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.